Cramer’s lighting round: Energy Transfer is a very good stock

Cramer’s lighting round: Energy Transfer is a very good stock


Nvidia Corp: “Nvidia is a terrific company but it sells at a very high price-to-earnings multiple. … We have pulled back a little bit [for the Charitable Trust].”

Blackstone Minerals Ltd: “I do not know Blackstone Minerals. I am going to have to do some more work on that situation.”

EVgo Inc: “Our biggest fear is, again, losing money, and it does not fit our criteria anymore for what we’re recommending.”

Energy Transfer LP: “ET is actually a very good stock. … Times change and it’s become a better, better stock.”

Medical Properties Trust Inc: “This one, I don’t like that particular part of the real estate investment trusts. I think that they are too high-yielding, which therefore causes me to be concerned that they will not be able to make the distribution.”

Axcelis Technologies Inc: “Some of these companies in this business are doing amazingly well. And you’ve got to hand it to them.”

Disclaimer: Cramer’s Charitable Trust owns shares of Nvidia.

Cramer's lightning round: Energy Transfer is a very good stock

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More
Wealthy donors stand to win double tax benefit if ‘Trump Accounts’ allow stock donations
Business

Wealthy donors stand to win double tax benefit if ‘Trump Accounts’ allow stock donations

President Donald Trump onstage at the Treasury Department’s Trump Accounts Summit, in Washington, Jan. 28, 2026. Kevin Lamarque | Reuters A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. With the Trump […]

Read More